Abstract
Ventricular septal defect (VSD), as the most common type of congenital heart disease (CHD), is mainly caused by cardiac dysplasia. Heart and neural crest derivatives expressed 2 (HAND2), as a member of the basic helix-loop-Helix (bHLH) gene family, participates in the development of the right heart. And the loss of HAND2 expression in humans is closely connected with ventricular septal defects. However, no studies have hitherto examined the association between VSD and HAND2 gene promoter. We used a case-control study to analyze the genetic variations of the HAND2 gene promoter region in VSD patients and controls. Using a variety of statistical analysis methods to analyze the association of single nucleotide polymorphisms (SNPs) with VSD. The dual luciferase reporter assay was used to conduct functional analysis of genetic variations. Electrophoretic mobility shift assay (EMSA) was used to examine DNA-protein interactions. Through sequencing, we identified nine genetic variants in patients with VSD. The SNP rs2276940 G>T and rs2276941 G>A were revealed to have associations with an increased risk of VSD. The dual luciferase reporter assay showed that the SNP rs2276940 G>T and rs138531627 C>G decreased the transcriptional activity of the HADN2 gene promoter. Transcription factors (TFs) predicting suggested that all three above SNPs may change the binding of the TFs. The result of EMSA showed that rs138531627 C>G may create a new binding site for TFs while rs2276940 G>T enhanced the binding affinity for TFs. All these results indicated that genetic variants of the HAND2 gene promoter increase VSD risk by reducing HAND2 expression, and the molecular mechanism may be the change of the binding affinity of TFs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (No.81870279). BY(BoYan) received the award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Human Ethic Committee of Affiliated Hospital of Jining Medical University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
